Search academic texts

Information × Registration Number 0215U006061, 0111U010492 , R & D reports Title To define features of hormone and metabolic disturbances at patients with somatomammotropinoma and prolactinoma at hyper- and hypoprolactinaemia popup.stage_title Head Khyzhnyak Oksana Olegovna, Registration Date 30-01-2015 Organization State Institution "V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine" popup.description2 The object of study: patients with hormonally active pituitary tumors (somatomammotropinomas and prolactinomas). Objective: according to the nature of the clinical course somatomammotrophin and prolactin and on the basis of the identified features hormonal and metabolic disorders occurring against the background of hyper - and hypoprolactinemia, grounded approach to optimal suppressive therapy in patients with these endocrinopathies. Methods: clinical, biochemical, hormonal, immuno, tools, statistics. It was conducted a retrospective analysis (in the last 20 years), long-term results of treatment with somatomammotropin and prolactin according to the data of clinic of the Institute. It was studied the clinical course and the formation of complications in patients with somatomammotropinomas and prolactinomas depending on sex, age, character and severity, duration of disease and treatments applied. It was studied the peculiarities of disorders of protein, fat, carbohydrate and water-salt metabolism with prolonged hyperprolactinemia in patients with somatomammotropinomas and prolactinomas. It was clarified the character of disorders of protein, fat, carbohydrate and water-salt metabolism in patients somatomammotropinomas and prolactinomas pharmacologically induced on hypoprolactinemia caused by the appointment of suppressive therapy with dopamine agonists. It was identified the effect of pharmacologically induced hypoprolactinemia on the cardiovascular system and the pituitary-thyroid system. It was analyzed world experience on suppressive therapy with dopamine agonists in patients with somatomammotropinomas and prolactinomas and around the world. It was justified the optimal duration of suppressive therapy with dopamine agonists necessary to prevent recurrence of the disease. Scope: health, endocrinology, neurosurgery, internal medicine. Product Description popup.authors Алексеєва Ірина Ігорівна Барабаш Надія Евгенівна Бастригіна Алла Олександрівна Гогітідзе Теона Гурамівна Завадська Наталія Володимирівна Зайцева Людмила Іванівна Курило Ольга Дмитрівна Микитюк Мирослава Ростиславівна Сидорова Ірина Василівна Тихонова Тетяна Михайлівна Тяжелова Ольга Володимирівна Ушакова Лора Григорівна Хижняк Оксана Олегівна popup.nrat_date 2020-04-02 Close